Risk of Sudden Cardiac Death in UN Athletes
Launched by UNIVERSIDAD NACIONAL DE COLOMBIA · Jul 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risk of sudden cardiac death in athletes, particularly those involved in high-performance sports. The goal is to find ways to identify athletes who may be at an increased risk of experiencing serious heart problems during their activities. The researchers will use a special heart test called a 12-lead electrocardiogram (ECG) to examine the heart's electrical activity and look for any issues that could lead to dangerous situations. Additionally, participants will fill out questionnaires about their personal and family health histories to help identify any other risk factors.
To participate in this study, athletes must be between 18 and 35 years old, have been training for over two years, and practice their sport for at least six hours each week. They should not have a history of certain medical conditions, including specific heart diseases or the use of certain medications. Participants can expect to undergo heart evaluations and complete health questionnaires, which will help create personalized risk profiles. This research is important because it aims to develop better strategies for keeping athletes safe and healthy during their sports activities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Athletes belonging to the sports teams of the National University of Colombia, Bogotá campus.
- • Subject's sports history (practice time exceeding 2 years).
- • Individuals aged 18 to 35 years, without discrimination based on biological sex.
- • Training time exceeding 6 hours per week in their sports modality (weekly training record).
- • Personal history of cardiovascular disease (cardiac malformations or previously detected sudden death risk).
- • Athletes who attend at least 90% of the training sessions planned by the coach.
- Exclusion Criteria:
- • Personal history of metabolic (type 1 and 2 diabetes mellitus), neurological (spinal cord injury), or renal disease.
- • Routine consumption of alcohol or psychoactive substances.
- • Use of antihypertensive medications, beta-blockers, or inotropes.
- • Cardiovascular disease diagnosed with previously established pharmacological management.
About Universidad Nacional De Colombia
The Universidad Nacional de Colombia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a leading clinical trial sponsor in Colombia. With a focus on advancing medical knowledge and improving healthcare outcomes, the university conducts rigorous clinical trials across various fields, including pharmacology, public health, and epidemiology. By leveraging its multidisciplinary expertise and state-of-the-art facilities, the Universidad Nacional de Colombia aims to foster collaborative research initiatives that address pressing health challenges both locally and globally, while adhering to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bogotá, Cundinamarca, Colombia
Patients applied
Trial Officials
Wilder Villamil-Parra, PhD.Sciences
Study Director
Universidad Nacional de Colombia
Erica Mancera-Soto, PhD.Sciences
Study Chair
Universidad Nacional de Colombia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported